Albert D. Dyrness's most recent trade in Hyperliquid Strategies Inc. was a trade of 40,789 Common Stock done . Disclosure was reported to the exchange on Feb. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Hyperliquid Strategies Inc | Albert D. Dyrness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 40,789 | 41,671 | - | 0 | Common Stock | |
| Hyperliquid Strategies Inc | Albert D. Dyrness | Director | Other type of transaction at price $ 0.00 per share. | 02 Dec 2025 | 882 | 882 | - | - | Common Stock | |
| Sonnet BioTherapeutics Holdings Inc | Albert D. Dyrness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 4,000 | 4,537 | - | - | Common Stock | |
| Sonnet BioTherapeutics Holdings Inc | D. Albert Dyrness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 373 | 537 | - | - | Common Stock | |
| Sonnet BioTherapeutics Holdings Inc | Albert D. Dyrness | Director | Purchase of securities on an exchange or from another person at price $ 0.47 per share. | 30 May 2023 | 23,255 | 28,962 | - | 0.5 | 10,883 | Common Stock |
| Sonnet BioTherapeutics Holdings Inc | Albert D. Dyrness | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2022 | 3,770 | 30,893 | - | - | Common Stock |